Cardiomyopathy which is characterized by dilation and contractile dysfunction of the left and right ventricles. It may be idiopathic, or it may result from a myocardial infarction, myocardial infectio...
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding dilated cardiomyopathy is largely due to its variable presentation and the fact that it affects a relatively small number of individuals. This rarity can hinder comprehensive clinical studies and systematic documentation of the condition's features and genetic underpinnings. As research evolves, there is hope for better understanding and management of this condition.
To navigate dilated cardiomyopathy, consider consulting a cardiologist with expertise in heart failure and cardiomyopathies. Engaging with a genetic counselor may also be beneficial, especially given the unclear genetic basis of the condition. While there are currently no patient organizations identified, you can explore resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional support and information. Participating in clinical trials may also provide access to new treatment options.
Currently, there is one orphan drug designated for dilated cardiomyopathy, trimetazidine, which is in development. Additionally, there are 79 active clinical trials exploring various aspects of this condition. For more information on these trials, you can visit the ClinicalTrials.gov search page at https://clinicaltrials.gov/search?cond=dilated%20cardiomyopathy.
Actionable guidance for navigating care for dilated cardiomyopathy
To navigate dilated cardiomyopathy, consider consulting a cardiologist with expertise in heart failure and cardiomyopathies. Engaging with a genetic counselor may also be beneficial, especially given the unclear genetic basis of the condition. While there are currently no patient organizations identified, you can explore resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional support and information. Participating in clinical trials may also provide access to new treatment options.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding dilated cardiomyopathy is largely due to its variable presentation and the fact that it affects a relatively small number of individuals. This rarity can hinder comprehensive clinical studies and systematic documentation of the condition's features and genetic underpinnings. As research evolves, there is hope for better understanding and management of this condition.
To navigate dilated cardiomyopathy, consider consulting a cardiologist with expertise in heart failure and cardiomyopathies. Engaging with a genetic counselor may also be beneficial, especially given the unclear genetic basis of the condition. While there are currently no patient organizations identified, you can explore resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional support and information. Participating in clinical trials may also provide access to new treatment options.
Currently, there is one orphan drug designated for dilated cardiomyopathy, trimetazidine, which is in development. Additionally, there are 79 active clinical trials exploring various aspects of this condition. For more information on these trials, you can visit the ClinicalTrials.gov search page at https://clinicaltrials.gov/search?cond=dilated%20cardiomyopathy.
Actionable guidance for navigating care for dilated cardiomyopathy
To navigate dilated cardiomyopathy, consider consulting a cardiologist with expertise in heart failure and cardiomyopathies. Engaging with a genetic counselor may also be beneficial, especially given the unclear genetic basis of the condition. While there are currently no patient organizations identified, you can explore resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional support and information. Participating in clinical trials may also provide access to new treatment options.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding dilated cardiomyopathy is largely due to its variable presentation and the fact that it affects a relatively small number of individuals. This rarity can hinder comprehensive clinical studies and systematic documentation of the condition's features and genetic underpinnings. As research evolves, there is hope for better understanding and management of this condition.
To navigate dilated cardiomyopathy, consider consulting a cardiologist with expertise in heart failure and cardiomyopathies. Engaging with a genetic counselor may also be beneficial, especially given the unclear genetic basis of the condition. While there are currently no patient organizations identified, you can explore resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional support and information. Participating in clinical trials may also provide access to new treatment options.
Currently, there is one orphan drug designated for dilated cardiomyopathy, trimetazidine, which is in development. Additionally, there are 79 active clinical trials exploring various aspects of this condition. For more information on these trials, you can visit the ClinicalTrials.gov search page at https://clinicaltrials.gov/search?cond=dilated%20cardiomyopathy.
Actionable guidance for navigating care for dilated cardiomyopathy
To navigate dilated cardiomyopathy, consider consulting a cardiologist with expertise in heart failure and cardiomyopathies. Engaging with a genetic counselor may also be beneficial, especially given the unclear genetic basis of the condition. While there are currently no patient organizations identified, you can explore resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional support and information. Participating in clinical trials may also provide access to new treatment options.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.